Johnson Investment Counsel Inc. Has $5.56 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Johnson Investment Counsel Inc. lessened its position in Pfizer Inc. (NYSE:PFE) by 5.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 151,473 shares of the biopharmaceutical company’s stock after selling 9,318 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Pfizer were worth $5,556,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. 25 LLC acquired a new position in shares of Pfizer during the 1st quarter worth approximately $25,000. Worth Asset Management LLC acquired a new position in shares of Pfizer during the 1st quarter worth approximately $29,000. Steward Financial Group LLC acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $43,000. GeoWealth Management LLC acquired a new position in shares of Pfizer during the 1st quarter worth approximately $49,000. Finally, Sanctuary Wealth Management L.L.C. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $50,000. Institutional investors and hedge funds own 68.05% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock traded up $0.15 on Friday, hitting $29.92. 27,082,355 shares of the company’s stock were exchanged, compared to its average volume of 31,586,170. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.38 and a quick ratio of 2.05. Pfizer Inc. has a 12 month low of $28.93 and a 12 month high of $54.93. The stock has a market cap of $168.94 billion, a P/E ratio of 16.36, a price-to-earnings-growth ratio of 1.91 and a beta of 0.63. The company has a 50 day moving average of $31.97 and a 200 day moving average of $35.28.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.15. Pfizer had a return on equity of 16.72% and a net margin of 15.30%. The business had revenue of $13.23 billion during the quarter, compared to the consensus estimate of $13.77 billion. On average, equities research analysts predict that Pfizer Inc. will post 1.56 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 4th. Shareholders of record on Friday, November 10th will be issued a $0.41 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.64 dividend on an annualized basis and a yield of 5.48%. Pfizer’s payout ratio is presently 89.62%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on PFE shares. TheStreet lowered Pfizer from a “b-” rating to a “c+” rating in a report on Monday, September 25th. Wells Fargo & Company decreased their target price on Pfizer from $39.00 to $35.00 and set an “equal weight” rating on the stock in a report on Monday, October 16th. JPMorgan Chase & Co. decreased their target price on Pfizer from $36.00 to $34.00 and set a “neutral” rating on the stock in a report on Monday, October 16th. StockNews.com assumed coverage on Pfizer in a research note on Thursday, October 5th. They issued a “hold” rating for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $75.00 price target on shares of Pfizer in a research note on Monday, October 2nd. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $42.50.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.